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ABSTRACT
The pandemic threat posed by emerging zoonotic influenza A viruses necessitates development of antiviral agents effective
against various antigenic subtypes. Human monoclonal antibody (hMAb) targeting the hemagglutinin (HA) stalk offers a prom-
ising approach to control influenza virus infections. Here, we investigated the ability of the hMAb 81.39a to inhibit in vitro repli-
cation of human and zoonotic viruses, representing 16 HA subtypes. The majority of viruses were effectively neutralized by
81.39a at a 50% effective concentration (EC50) of <0.01 to 4.9 g/ml. Among group 2 HA viruses tested, a single A(H7N9) virus
was not neutralized at 50 g/ml; it contained HA2-Asp19Gly, an amino acid position previously associated with resistance to
neutralization by the group 2 HA-neutralizing MAb CR8020. Notably, among group 1 HA viruses, H11-H13 and H16 subtypes
were not neutralized at 50 g/ml; they shared the substitution HA2-Asp19Asn/Ala. Conversely, H9 viruses harboring HA2-
Asp19Ala were fully susceptible to neutralization. Therefore, amino acid variance at HA2-Asp19 has subtype-specific adverse
effects on in vitro neutralization. Mice given a single injection (15 or 45 mg/kg of body weight) at 24 or 48 h after infection with
recently emerged A(H5N2), A(H5N8), A(H6N1), or A(H7N9) viruses were protected from mortality and showed drastically re-
duced lung viral titers. Furthermore, 81.39a protected mice infected with A(H7N9) harboring HA2-Asp19Gly, although the anti-
viral effect was lessened. A(H1N1)pdm09-infected ferrets receiving a single dose (25 mg/kg) had reduced viral titers and showed
less lung tissue injury, despite 24- to 72-h-delayed treatment. Taken together, this study provides experimental evidence for the
therapeutic potential of 81.39a against diverse influenza A viruses.
IMPORTANCE
Zoonotic influenza viruses, such as A(H5N1) and A(H7N9) subtypes, have caused severe disease and deaths in humans, raising
public health concerns. Development of novel anti-influenza therapeutics with a broad spectrum of activity against various sub-
types is necessary to mitigate disease severity. Here, we demonstrate that the hemagglutinin (HA) stalk-targeting human mono-
clonal antibody 81.39a effectively neutralized the majority of influenza A viruses tested, representing 16 HA subtypes. Further-
more, delayed treatment with 81.39a significantly suppressed virus replication in the lungs, prevented dramatic body weight
loss, and increased survival rates of mice infected with A(H5Nx), A(H6N1), or A(H7N9) viruses. When tested in ferrets, delayed
81.39a treatment reduced viral titers, particularly in the lower respiratory tract, and substantially alleviated disease symptoms
associated with severe A(H1N1)pdm09 influenza. Collectively, our data demonstrated the effectiveness of 81.39a against both
seasonal and emerging influenza A viruses.
Influenza A viruses of 16 hemagglutinin (HA) and nine neur-aminidase (NA) antigenic subtypes have been detected in a vast
natural reservoir of aquatic birds. Eight highly diverse HA sub-
types are known to have caused infections in humans (H1, H2,
H3, H5, H6, H7, H9, and H10); some of these subtypes (H1, H2,
and H3) have caused pandemics and recurrent epidemics with
various levels of severity. Interspecies transmission and zoonosis
are central to the emergence of new viruses in humans. For exam-
ple, a swine-origin virus contributed to the genesis of the 2009
H1N1 pandemic [A(H1N1)pdm09] and continues to circulate
among humans (1). Since 2013, China has experienced four waves
of outbreaks caused by avian A(H7N9) viruses despite significant
control measures. More recently, subclade 2.3.4.4 highly patho-
genic avian influenza (HPAI) H5 viruses were detected in several
countries in Europe and Southeast Asia (2) and were detected for
the first time in wild birds and poultry in North America, where
they inflicted a significant economic burden on the poultry indus-
try (2) and raised concerns over potential human infections. Fur-
thermore, in January 2016, both HPAI and low-pathogenicity
avian influenza (LPAI) A(H7N8) viruses were detected in turkey
flocks in Indiana, USA. As with HPAI virus of the H5 subtype, this
is the first instance of HPAI A(H7N8) virus detection in poultry,
whereas LPAI A(H7N8) virus has been detected previously in wild
bird surveillance in the U.S.
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Antiviral therapy has been a valuable component of the ongo-
ing efforts to reduce the burden of disease caused by influenza
virus infections in humans. Antiviral agents have the potential to
provide a key defense at times when vaccination is not effective at
preventing infection in individuals or is not available. The current
treatment options in the U.S. are limited to M2 protein blockers
and NA inhibitors (NAIs). These two classes of influenza drugs are
represented by small molecules that target highly conserved re-
gions of two viral surface proteins, a transmembrane domain of
M2 and a catalytic site of NA. The NAIs oseltamivir (oral) and
zanamivir (inhaled) were the first two FDA-approved antivirals
for treating influenza infections, with oseltamivir being the most
widely prescribed. Intravenous peramivir has also recently been
FDA approved, while intravenous zanamivir is undergoing clini-
cal evaluation but has been available for compassionate use in
patients with serious influenza-related illness (3). The intravenous
route of drug administration is viewed as the most convenient in
treating severely ill patients.
Resistance to M2 blockers is widely present among seasonal
influenza A viruses, and the U.S. Centers for Disease Control and
Prevention (CDC) has not recommended their use since the 2005-
2006 influenza season (4). Moreover, many HPAI H5N1 and
swine-origin viruses are also M2 resistant (5, 6). Resistance to
NAIs, especially oseltamivir, has been detected in viruses follow-
ing patient treatment (7, 8), and widespread oseltamivir resistance
occurred in seasonal A(H1N1) viruses prior to the emergence of
A(H1N1)pdm09 (9, 10). These drugs should be administered
early after viral infection to achieve the optimal therapeutic ben-
efits (11, 12). Concerns of widespread resistance, reported side
effects, and the less than desirable potency of NAIs emphasize the
need to expand therapeutic options, especially for the most vul-
nerable patient populations. Antiviral agents with new mecha-
nisms of action that are also efficacious against a broad spectrum
of influenza virus subtypes are preferred. Therefore, efforts to find
antivirals that interfere with HA protein function are desirable
despite the genetic/structural diversity and continuous evolution
of this protein. To this end, the development of human monoclo-
nal antibodies (MAbs) with a broad spectrum of anti-HA activity
is promising.
The 16 HA subtypes are divided into groups 1 and 2 based on
their phylogenetic relationship: group 1 encompasses H1, H2, H5,
H6, H8, H9, H11, H12, H13, and H16, while group 2 includes H3,
H4, H7, H10, H14, and H15 (13). The influenza virus HA is a
trimeric type I transmembrane glycoprotein formed by identical
HA0 molecules, which are cleaved by host proteases into HA1 and
HA2 subunits (14). The HA1 subunit forms a membrane-distal
globular head that contains the receptor-binding site and most of
the highly variable immunodominant antigenic regions recog-
nized by neutralizing antibodies (15, 16). These antibodies are
typically strain or subtype specific. Conversely, the HA2 subunit
consists of a highly conserved stalk-like structure, which anchors
the globular domain to the viral membrane (17, 18). HA2 contrib-
utes to the stalk region that carries out the membrane fusion func-
tion; generally, antibodies raised to this highly conserved region
are broadly neutralizing. While broadly neutralizing antibodies
(bnAbs) represent only a small fraction of the antibodies raised
(19, 20), their discovery has expanded interest in bnAbs as poten-
tial antiviral drugs.
Further advancement has been achieved with discoveries of
fully human MAbs that neutralize viruses of both HA groups.
These MAbs are 39.29 and 81.39 (21); FI6v3 (22); CR9114 (23);
PN-SIA-28 (24); CT149 (25); VIS410 (26, 27); 045-051310-2B06
and S6-B01 (28); 05-2G02 (29); 07-5E01, 41-5D06, and 41-5E04
(30); HV6-1HD3-3, HV1-18HD3-9, and HV1-18 (Q-x-x-V)
(31); and MEDI8852 (32). Nonetheless, their antiviral activities
against all known subtypes of influenza A viruses has not been
completely characterized. While the in vivo effectiveness of these
broadly neutralizing antibodies has been tested using mouse (e.g.,
for MAbs CR9114, CT149, FI6v3, 39.29, and VIS410) and ferret
(e.g., for MAbs FI6, 39.29, 81.39) models, studies with additional
challenge viruses are warranted.
Nakamura et al. described a human-plasmablast enrichment
technique that allowed the identification of two stalk-targeting
MAbs, 39.29 and 81.39, with neutralizing activity against
A(H1N1) (group 1) and A(H3N2) (group 2) influenza viruses in
vitro. The structural analysis showed that 39.29 and 81.39 MAbs
utilized the same germ lines, with each containing 12 to 15 variable
heavy-chain and 7 to 9 variable light-chain mutations (21). The
therapeutic effect of 39.29 was tested against A(H1N1) (group 1)
and A(H3N2) (group 2) subtypes in mice, while both 39.29 and
81.39 were tested in ferrets infected with an HPAI A(H5N1)
(group 1) virus. A single-dose administration of either MAb in a
postexposure treatment model was superior to repetitive treat-
ment with oseltamivir (21). However, the neutralization activity
of these MAbs against other influenza subtypes has not been elu-
cidated, and their efficacy against newly emerging zoonotic influ-
enza viruses is not known.
Here, we show that human IgG1 MAb 81.39a, a derivative of
the parental 81.39, exerts a broadly neutralizing activity against a
large panel of influenza A viruses covering 16 HA subtypes, in-
cluding the emerging clade 2.3.4.4 HPAI H5Nx, HPAI A(H7N8),
and A(H7N9) viruses. Here, we observed differences in 81.39a
neutralization profiles and provide the molecular basis of
81.39a activity in vitro. Furthermore, we demonstrated that a
single administration of 81.39a protected mice and ferrets against
lethal challenge with A(H1N1)pdm09, HPAI A(H5N2), HPAI
A(H5N8), A(H6N1), and A(H7N9) influenza viruses. These stud-
ies provide further insight into the breadth of the antiviral activity
of 81.39a and expand our understanding of this stalk-targeting
MAb as a promising therapeutic option against seasonal and
emerging influenza viruses.
MATERIALS AND METHODS
Ethics statements. Animal experiments were conducted in strict compli-
ance with guidelines of the CDC Institutional Animal Care and Use Com-
mittee in association with the PHS Policy, the Animal Welfare Act
(USDA), and the Guide for Animal Care and Use of Laboratory Animals
(33). Animal protocols were approved by the CDC IACUC committee.
Animal welfare was observed on a daily basis until study completion. All
procedures involving zoonotic influenza viruses were performed under
animal biosafety level 3 enhanced (ABSL3) conditions and in an ABSL2
facility when working with seasonal viruses. Manipulation of animals and
collection of organ tissues were conducted within a biosafety cabinet.
Viruses and sequence analysis. Seasonal and zoonotic influenza vi-
ruses used in this study were submitted to the WHO Collaborating Center
for Surveillance, Epidemiology, and Control of Influenza at the Centers
for Disease Control and Prevention (CDC) for virological surveillance,
which includes antigenic characterization and antiviral susceptibility test-
ing. Non-U.S. viruses were kindly shared with the CDC by the responsible
authorities in designated countries. Two A(H7N9) clones of A/Taiwan/1/
2013 virus used in this study were isolated using biological cloning
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(plaque purification) procedures. All viruses were propagated in Madin-
Darby canine kidney (MDCK) cells (ATCC, VA) and underwent a limited
number of passages in cultured cells to maintain their original properties.
At least viral HA and NA gene sequences were confirmed by Sanger se-
quencing generated using an ABI Prism 3730 genetic analyzer (Applied
Biosystems, Foster City, CA) and assembled using Sequencher 5.0 (Gene
Codes Corporation, Ann Arbor, MI). The amino acid substitution(s) was
corroborated using the pyrosequencing method as previously described
(34, 35). Protein sequences for viral HA of H9, H12, and other virus
subtypes used for HA2 sequence analyses were downloaded from the pub-
lic database Global Initiative on Sharing All Influenza Data (GISAID).
Human monoclonal antibody. The broadly neutralizing human
81.39a (IgG1) MAb for influenza A viruses was generated, purified, and
produced in large quantity as previously described (21). Anti-influenza B
virus MAb was used as a negative control in focus and virus yield reduc-
tion assays. Control IgG (gD5237), a MAb specific for glycoprotein D of
herpes simplex virus (21), was applied for all in vivo studies.
Virus neutralization and inhibition of viral replication in cell cul-
ture. The neutralization properties of 81.39a against 16 virus subtypes
were examined using the focus reduction assay. Briefly, confluent MDCK-
SIAT1 cell monolayers in 24-well plates were incubated with a mixture of
5-fold serial dilutions of MAb at 0.08 to 500 g/ml and pretitrated virus
(30 to 60 foci/well), which was allowed to react for 1 h at room tempera-
ture, for 1 h at 37°C. After removal of virus-MAb mixture, overlay (0.5%
Avicel in 1 Eagle’s modified essential medium [EMEM]; ATCC, VA)
containing MAb was added to the cells, and they were further incubated
for 16 to 20 h at 37°C. Overlay then was removed, and cells were washed
and fixed. Visualization of infected cells was done by immunostaining
with mouse anti-viral nucleoprotein (NP) antibody blend (MAB8251;
Millipore, CA), followed by incubation with anti-mouse IgG (Fab specif-
ic)-fluorescein isothiocyanate (FITC) antibody (Sigma, MO). The num-
ber of foci (a focus is a cluster of five or more infected cells) was counted
under a fluorescence microscope.
A virus yield reduction assay was applied to assess the inhibitory effect
of 81.39a on virus replication in MDCK-SIAT1 cells. After 1 h of inocu-
lation at 37°C as described above, the inoculum was replaced with fresh
cell culture medium containing MAb, and cells were incubated for 24 h at
37°C. Thereafter, supernatants were collected and used for virus titration
using the 50% tissue culture infectious dose (TCID50) assay.
Infection, MAb treatment, and collection of tissue samples in mice.
Six- to 8-week-old female BALB/c mice (Charles River, MA) were housed
and monitored for at least 3 days for acclimation prior to the start of the
study. Groups of 22 mice were inoculated with 105.6 50% egg infectious
doses (EID50) (4.0 50% mouse lethal doses [MLD50]) of H5N2 virus or
106.6 EID50 (1.6 MLD50) of A(H5N8) virus. Mice were then treated with
either 81.39a (45 mg/kg of body weight) or control IgG (gD5237; 45 mg/
kg) at 24 days postinoculation (dpi) via intravenous (tail vein) injection
(50 l/mouse) under anesthesia. Lungs (n  12/treatment group) were
collected at days 3 and 6 (6 mice per test day) as previously described (36).
In the second set of experiments, groups of 14 mice were inoculated
with 105.1 TCID50 of A(H6N1) or 10
5.2 TCID50 of A(H7N9) virus; both
inoculation doses corresponded to 5.0 MLD50. The experiment with
A(H7N9) virus was done in duplicate, using 10 mice per group for the
second round. 81.39a (15 or 45 mg/kg) or control IgG (45 mg/kg) was
given once at 48 h postinoculation (hpi). Mice infected with A(H6N1)
virus were treated only with the higher MAb concentration. Lungs (n 
6/treatment group) were collected at days 5 and 7 pi; for H7N9-infected
mice, lungs were collected only from the first experiment. Viral titers in
lung homogenates were determined using the TCID50 assay. Mice were
observed daily for clinical signs and survival throughout the study.
Infection, treatment, and collection of nasal wash, blood, and tissue
samples in ferrets. Groups of four male ferrets (Mustela putorius furo)
aged 3 to 5 months (Triple F Farms, PA), and serologically negative by
hemagglutination inhibition (HI) assay for currently circulating influenza
A(H1N1)pdm09, A(H3N2), and B viruses, were used in this study. Ferrets
were housed in customized, individual cages (Allentown Inc., Allentown,
PA) and monitored for at least 3 days for acclimation and to establish
baseline body temperatures prior to the start of the study. Clinical signs of
illness and body weight were recorded daily. The following activity status
scores were used: 0, alert and playful; 1, alert and playful only when stim-
ulated; 2, alert but not playful when stimulated; 3, neither alert nor
playful when stimulated. Nasal and ocular discharge, sneezing, cough-
ing, dyspnea (shortness of breath), and diarrhea were scored 0 if not
present or 1 if present. The temperature was measured twice daily by
subcutaneous implantable temperature transponders (Bio Medic Data
Systems, Seaford, DE).
Intranasal inoculation was performed under anesthesia, induced by
intramuscular administration of a ketamine-xylazine-atropine mixture
(25 mg/kg, 2 mg/kg, and 0.05 mg/kg, respectively), using 106 TCID50 of
virus diluted in sterile phosphate-buffered saline (PBS) (0.5 ml total vol-
ume). The A(H1N1)pdm09 virus was used in this study. The infected
ferrets were then divided into four groups (four animals per group): con-
trol IgG (gD5237; 25 mg/kg) given at 1 dpi and 81.39a (25 mg/kg) given at
24, 48, and 72 hpi. The antibodies (1.5 ml total volume) were adminis-
tered once via intravenous injection through the cranial vena cava.
Nasal washes were collected daily (under anesthesia) by flushing nos-
trils with 1 ml of sterile PBS and further processed for determination of
infectious viral titers using TCID50 assay. Under anesthesia, all animals
from each group were thoroughly exsanguinated prior to euthanization at
5 dpi, and viral titers were determined in nasal turbinates, trachea, and
lung bronchoalveolar lavage fluid (BALF). The BALF was centrifuged at
1,000  g for 10 min, and the inflammatory cell count and protein con-
centration in cell-free solution were determined. Harvested whole lungs
were fixed in 10% neutral buffered formalin and used for histopathology
and immunohistochemistry.
Histopathology and immunohistochemistry. Histopathology and
detection of viral NP in the lung (immunohistochemistry) were per-
formed at the Yerkes National Primate Research Center (Emory Univer-
sity, GA) according to procedures published previously (37). Briefly, the
whole lungs were collected immediately after euthanization, fixed by sub-
merging the tissues in 10% neutral buffered formalin, and embedded in
paraffin. Five-micrometer sections of each lung lobe were taken and
stained with hematoxylin and eosin (H&E). For immunohistochemistry
staining, lung sections were stained with multisubtype mouse anti-NP
antibody (1:1,000 dilution; MAB8251; Millipore, CA) by incubating them
at room temperature for 1 h. The labeled tissue sections were stained with
Mouse Mach2 (Biocare Medical), and all reactions were detected by de-
velopment of the chromogen (Warp Red; Biocare Medical). Appropriate
positive and negative controls were run in parallel. The nuclei were then
counterstained using Gill’s hematoxylin. Pathological scores were deter-
mined as described previously (38). Percent lung affected, severity of al-
veolitis and bronchiolitis/bronchitis, and extent of peribronchial and
peribronchiolar/perivascular infiltrates were given the following scores: 0,
no lesions; 1, 25%; 2, 25 to 50%; 3, 50%. Alveolar edema, hemorrhage,
and type 2 pneumocyte hyperplasia were scored 0 if not present or 1 if
present.
Statistical analysis. Statistics were performed using the GraphPad
Prism v.5.0. software, and the statistically significant difference was set at
an alpha of 0.05 (P  0.05). The unpaired two-tailed Student’s t test was
applied to evaluate the statistical significance in viral titers and other an-
alyzed parameters of control IgG- and 81.39a-treated animals. The sur-
vival fractions were estimated by the Kaplan-Meier method and com-
pared between treatment groups within the same virus strain using the
log-rank (Mantel-Cox) test.
RESULTS
81.39a demonstrates broad-spectrum antiviral activity in vitro.
To assess the breadth of 81.39a activity against multiple subtypes,
we evaluated its ability to neutralize a panel of influenza A viruses
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of group 1 and 2 HAs isolated between 1960 and 2015 (Table 1).
The panel represented influenza viruses of 16 HA and nine NA
subtypes and included isolates with known markers of resistance
to FDA-approved NAI. The determined EC50s varied widely
among viruses tested; however, the infectivity of a majority of
viruses was neutralized by 50% at concentrations below 5 g/ml.
H5 (0.10 to 0.22 g/ml) and H4 (0.01 g/ml) subtypes were the
most sensitive to neutralization in HA groups 1 and 2, respec-
TABLE 1 Activity of 81.39a against influenza A viruses of group 1 and 2 HAs in cell culturea
Clade and strain designation Subtype
Resistance markerd
81.39a EC50
b
(g/ml)
Amino acid
at position
HA2–19
c
Accession number in GISAIDe
NA M2 HA NA M
Group 1 HA
A/California/12/2012 A(H1N1)pdm09 S31N 1.29 	 0.23 D EPI397889 EPI397888 EPI397887
A/Texas/23/2012 A(H1N1)pdm09 H274Y S31N 0.75 	 0.24 D EPI397892 EPI397891 EPI397890
A/Maryland/08/2013 A(H1N1)pdm09 S31N 0.58 	 0.04 D EPI507529 EPI507528 EPI508430
A/Louisiana/08/2013 A(H1N1)pdm09 H274Y S31N 0.59 	 0.43 D EPI507531 EPI507530 EPI515738
A/Minnesota/14/2012 A(H1N2)v S31N 3.01 	 0.47 D EPI395306 EPI395305 EPI395302
A/Ann Arbor/6/1960 A(H2N2) 1.36 	 0.27 D EPI400083 EPI400085 EPI400084
A/Vietnam/1203/2004 A(H5N1) L26I and
S31N
0.13 	 0.03 D EPI123515 EPI116648 EPI25613
A/duck/Vietnam/NCVD-664/2010
(2.3.2.1a)
A(H5N1) H274Y 0.22 	 0.05 D EPI424370 EPI424369 EPI424365
A/duck/Vietnam/NCVD-680/2011
(2.3.2.1a)
A(H5N1) 0.16 	 0.05 D EPI424378 EPI424377 EPI424373
A/northern pintail/Washington/40964/2014
(2.3.4.4)
A(H5N2) S31N 0.22 	 0.09 D EPI569383 EPI569385 EPI569386
A/gyrfalcon/Washington/41088–6/2014
(2.3.4.4)
A(H5N8) S31N 0.10 	 0.02 D EPI569390 EPI569392 EPI569393
A/Taiwan/2/2013 A(H6N1) S31N 1.93 	 0.89 D EPI459855 EPI459857 EPI459858
A/garganey/Ukraine/05835-NAMRU3/2006 A(H8N4) 0.31 	 0.07 D EPI372512 EPI372511 EPI372507
A/chicken/Vietnam/NCVD-1156/2011 A(H9N2) S31N 0.08 	 0.03 A EPI457483 EPI457482 EPI457478
A/chicken/Bangladesh/OP-4/2013 A(H9N2) S31N 1.0 A EPI744942 EPI744941 EPI744940
A/environment/Bangladesh/OE-09/2013 A(H9N2) S31N 1.0 A EPI744945 EPI744944 EPI744943
A/quail/Bangladesh/337/2013 A(H9N2) 1.0 A EPI744948 EPI744947 EPI744946
A/Hong Kong/308/2014 A(H9N2) S31N 0.11 	 0.02 A EPI498037 EPI498036 EPI498032
A/duck/Bangladesh/1595/2010 A(H11N3) S31N 50 N EPI540159 EPI540158 EPI540154
A/mallard/Alberta/60/1976 A(H12N5) 50 A EPI744935 EPI744934 NS
A/lesser flamingo/Kenya/54/2008 A(H12N2) Unknown 50 A EPI744937 EPI744936 NS
A/shorebird/Delaware/68/2004 A(H13N9) 50 N EPI744939 EPI744938 NS
A/shorebird/Delaware/172/2006 A(H16N3) 50 N EPI407987 EPI407997 EPI407996
Group 2 HA
A/Wuhan/359/1995-like A(H3N2) 1.23 	 0.18 D EPI828813 EPI828814 NS
A/Wuhan/359/1995-like A(H3N2) E119V 1.06 	 0.11 D EPI828815 EPI828816 NS
A/Bethesda/956/2006 A(H3N2) S31N* 4.85 	 0.31 D EPI746386 EPI244127 NS
A/Texas/12/2007 A(H3N2) E119V S31N 0.84 	 0.11 D EPI466983 EPI466982 EPI466981
A/Ohio/88/2012 A(H3N2)v S247P S31N 2.83 	 0.83 D EPI397961 EPI397960 EPI397957
A/turkey/Minnesota/833/1980 (clone 1) A(H4N2) R292K* 0.01 D EPI240428 NS EPI240272
A/turkey/Minnesota/833/1980 (clone 2) A(H4N2) 0.01 D EPI243157 EPI243159 EPI243160
A/turkey/Indiana/1573–02/2016 A(H7N8) 0.15 	 0.01 D EPI744951 EPI744950 EPI744949
A/turkey/Indiana/1403/2016 A(H7N8) 0.28 	 0.02 D EPI744954 EPI744953 EPI744952
A/Anhui/1/2013 A(H7N9) 3.93 	 1.85 D EPI439507 EPI439509 EPI439506
A/Shanghai/1/2013 (clone 27) A(H7N9) S31N 0.3 	 0.19 D EPI744956 EPI503954 EPI744955
A/Shanghai/1/2013 (clone 1) A(H7N9) R292K S31N 0.66 	 0.12 D EPI439486 EPI439487 EPI439493
A/Taiwan/01/2013 (clone 33) A(H7N9) S31N 0.83 	 0.25 D EPI515454 EPI503953 EPI515448
A/Taiwan/01/2013 (clone S2) A(H7N9) R292K S31N 50 G EPI516362 EPI503956 EPI516364
A/Hong Kong/734/2014 A(H7N9) S31N 1.71 	 0.19 D EPI498800 EPI498799 EPI498795
A/duck/Vietnam/NCVD-0035/2012 A(H10N7) 0.43 	 0.1 D EPI744933 EPI744932 EPI744931
A/garganey/Ukraine/05839-NAMRU3/2006 A(H14N6) 0.14 	 0.02 D EPI372520 EPI372519 EPI372515
A/shearwater/West Australia/2576/1979 A(H15N9) Unknown 0.61 	 0.23 D EPI184623 EPI184640 NS
a The EC50 data were generated in neutralization assays. The 81.39a antibody was present throughout viral replication cycles. Influenza B virus-specific antibody was used as an IgG
control.
b Each data point 	 standard deviation represents the mean EC50 done in triplicate.
c The HA2-D19A/G/N amino acid substitutions are shown in boldface.
d Asterisks indicate molecular markers of resistance to NAIs (NA) and/or M2 inhibitors (M2) as determined using pyrosequencing assay.
e NS, not sequenced.
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tively. Notably, a total of 6 viruses representing five HA subtypes
were not neutralized at 50 g/ml, the highest concentration of
81.39a tested (Table 1); they were H11, H12, H13, and H16 sub-
types of group 1 HA and A(H7N9) of group 2 HA. It is noteworthy
that, for A(H7N9), the mean EC50 for five other strains tested in
the neutralization assays was 1.5 g/ml, suggesting strain-specific
neutralization of MAb 81.39a. Overall, 81.39a neutralized the ma-
jority of influenza viruses of group 1 and 2 HAs tested in vitro,
signifying its broad-spectrum antiviral activity.
Sequence analysis of viruses with reduced in vitro suscepti-
bility. The observed subtype- and strain-specific neutralization
pattern prompted further investigation to identify a molecular
basis for the reduced neutralizing activity. As 81.39a has predi-
cated binding to the HA stalk region (26), we analyzed HA se-
quences of all tested viruses and aligned sequences within the stalk
region to examine amino acid differences. Our analysis showed
that all six viruses that were not neutralized shared a substitution
at position 19 in HA2 (HA2 numbering starting from the HA0
cleavage site) (Table 1). Specifically, HA2-Asp19Asn was found in
H11, H13, and H16 subtype viruses; these three subtypes form
cluster H1b of group 1 (39, 40). Two H12 subtype viruses tested
had HA2-Asp19Ala; this subtype belongs to cluster H9 of group 1
HA (40). An A(H7N9) virus, A/Taiwan/1/2013 (clone S2), pos-
sessed HA2-Asp19Gly (Table 1).
We next compared the 81.39a neutralization potency against
two clones of A/Taiwan/01/2013 [A(H7N9)] influenza virus that
differed by a single amino acid substitution in HA2 using a focus-
forming reduction assay (Table 2). While clone C7 possessed
HA2-Asp19 (wild type), clone S2 possessed HA2-Asp19Gly. In the
first set of experiments, the maximum MAb concentration tested
was 50 g/ml. As shown in Table 2, 50% of the HA2-Asp19 clone
virus was inhibited by 3.55 g/ml of 81.39a (61% reduction in
focus number; range, 47 to 76%). The 50 g/ml concentration of
MAb failed to reach the 50% (32% reduction in focus number;
range, 19 to 44%) infectivity inhibition for the HA2-Asp19Gly
clone compared to that of the control (infected, untreated cells).
In the second set of experiments the maximal concentration of
81.39a was increased to 300 g/ml. We found that the number of
foci produced by the HA2-Asp19Gly clone in cells treated with 300
g/ml of 81.39a was much lower. Approximately 48% inhibition
(range, 22% to 54%) was observed. The results confirmed that the
HA2-Asp19Gly substitution reduced the ability of the MAb to
neutralize virus infectivity in vitro.
Polymorphism frequencies at position HA2-Asp19 among
influenza A viruses. To understand the frequency of amino acid
polymorphisms at residue 19 in the HA2 protein, we examined HA
sequences deposited in GISAID as of 12 November 2015. The
majority (99%) of H7N9 viruses recovered from humans (n 
231) maintained HA2-Asp19; only two viruses, A/Jiangsu/02/2013
and A/Wuxi/1/2013, contained Asp19Asn, and a single virus,
A/Shenzhen/SP39/2014, had Asp19Gly. Conversely, all HA se-
quences of H11 (n  619), H13 (n  176), and H16 (n  58)
viruses possessed Asn, while all H12 subtype sequences (n  150)
possessed Ala at this position. Peculiarly, while the H12 subtype
belongs to the H9 cluster of group 1 HA, the presence of Ala19 in
the A(H9N2) viruses tested had no effect on virus neutralization
(Table 1). The majority (99%) of H9 subtype viruses recovered
from humans and other species possessed Ala19 (over 3,000 HA
sequences).
Therapeutic efficacy of 81.39a against group 1 HA influenza
A viruses in mice. Because in vitro neutralization is not always
predictive of in vivo effectiveness of influenza antivirals, we tested
the efficacy of 81.39a against emerging zoonotic influenza A vi-
ruses. First, we evaluated the therapeutic efficacy of 81.39a against
HPAI A(H5) viruses as a representative of group 1 HA viruses.
Mice were inoculated with either an A(H5N2) (A/northern pin-
tail/Washington/40964/2014) or A(H5N8) (A/gyrfalcon/Wash-
ington/41088-6/2014) influenza virus and given a single intrave-
nous dose of 81.39a (45 mg/kg) at 24 hpi. 81.39a administration
protected 100% of animals from death (Fig. 1C and F). Of note, in
the control IgG (gD5237)-treated groups, 90% of A(H5N2)-inoc-
ulated and 50% of A(H5N8)-inoculated animals survived the in-
fection, confirming previous results that recent clade 2.3.4.4
A(H5N2) and A(H5N8) viruses detected in North America dem-
onstrate a moderate pathogenicity phenotype in mice (36) com-
pared to other Eurasian-lineage HPAI A(H5) viruses. Both
A(H5N2) and A(H5N8) viruses replicated efficiently in the lungs
of control mice at 3 and 6 dpi; their mean titers ranged from 5.2 to
6.1 log10 (Fig. 1A and D). Treatment with 81.39a significantly
reduced mean viral titers in the lungs up to 3 log10 at day 3 (P 
0.0001 for both viruses) and virus was not detected (5 log10
reduction) at day 6 (P  0.0001 for both viruses), indicating that
81.39a controlled virus spread in the lower respiratory tract of
mice. Further, 81.39a treatment prevented body weight loss (Fig.
1B and E), and 81.39a-treated mice recovered much faster from
the disease than those in the control groups.
The 81.39a efficacy against another group 1 HA virus (A/
Taiwan/2/2013) of A(H6N1) subtype was also tested in mice. In
this experiment, the same dose (45 mg/kg) of antibody as that used
for H5-infected animals was administered at 48 hpi. As expected,
control IgG-treated animals exhibited more severe signs of disease
and succumbed to infection between 8 and 9 dpi (Fig. 1I). Con-
TABLE 2 Neutralization activity of 81.39a against A(H7N9) virusesa
Expt no. and H7N9 virus
Amino acid at
HA2–19
No. of foci at the indicated concertation of 81.39ab (% inhibition; range)
EC50 (g/ml)0 g/ml 50 g/ml 300 g/ml
1
A/Taiwan/01/2013 (clone C7) D 43.7 	 5.4 17.0 	 3.6 (61; 47–76) NT 3.55 	 0.85
A/Taiwan/01/2013 (clone S2) G 45.7 	 2.6 31.3 	 3.1 (32; 19–44) NT 50
2
A/Taiwan/01/2013 (clone C7) D 48.0 	 10.2 15.7 	 3.7 (67; 47–82) 8.3 	 1.7 (83; 74–90) 3.06 	 0.63
A/Taiwan/01/2013 (clone S2) G 51.3 	 2.1 43.3 	 2.1 (16; 6–24) 32.0 	 5.4 (48; 22–54) 300
a Virus was preincubated for 1 h with 81.39a, followed by 1 h of virus adsorption. The MAb was present in cell overlay throughout the experiment.
b Mean number of foci derived from at least three replicates for each virus per experiment. Values are compared to those in untreated (0 g/ml) cells. NT, not tested.
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FIG 1 Effectiveness of 81.39a treatment in mice. Viral titers in lungs (A, D, G, J, and M), change in body weight (B, E, H, K, and N), and survival (C, F, I, L, and
O) of mice inoculated with 105.6 EID50 of H5N2 (A to C), 10
6.6 EID50 of H5N8 (D to F), 10
5.1 TCID50 of H6N1 (G to I), 10
5.2 TCID50 of A(H7N9) wild-type (J
to L), or 105.2 TCID50 of A(H7N9) HA2-Asp19Gly (M to O) virus and treated at 24 hpi for A(H5N2), A(H5N8), and A(H6N1) or 48 hpi for A(H7N9) with 81.39a
at the indicated dose. All data are expressed as the means 	 SD. (A and B) Representative results from an experiment with 22 mice per group. (C) Representative
results from an experiment with 14 mice per group. (D and E) Representative results from two independent experiments with 10 to 14 mice per group. Dotted
lines in lung viral titers indicate the limit of detection (1.6 log10). *, P  0.05; ND, not determined.
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versely, 81.39a treatment protected 90% of infected animals and
prevented significant weight loss (Fig. 1H). Compared to the con-
trol group, 81.39a significantly reduced mean viral titers in the
lungs of A(H6N1)-inoculated mice at 5 dpi (3 log10; P 
0.0001); no virus was detected at 7 dpi (5 log10 reduction; P 
0.0001) (Fig. 1G). Altogether, these data show that 81.39a was
effective in mice infected with a group 1 HA influenza virus.
Therapeutic efficacy of 81.39a against group 2 HA influenza
A virus in mice. Antiviral efficacy of 81.39a against group 2 influ-
enza virus was evaluated in the A(H7N9) lethal model. Two doses,
15 and 45 mg/kg, were given to animals at 48 hpi. Viral titers in
lungs were determined at 5 and 7 dpi, and morbidity and mortality
were monitored for 14 days. To maximize the translational rele-
vance, we used both HA2-Asp19 (wild type) and HA2-Asp19Gly
A(H7N9) (A/Taiwan/1/2013) influenza viruses in our experi-
ments.
The experiment with each virus was performed in duplicate.
Both viruses replicated to comparably high titers in lungs of mice
(Fig. 1J and M). Moreover, they showed a similar level of viru-
lence, as judged by body weight loss and survival (Fig. 1K, L, N,
and O). Treatment of wild-type-infected mice with 81.39a re-
sulted in a dose-dependent inhibition in viral titers in lungs at 5
dpi with mean titers reduced by 0.9 log10 (P  0.004) and 3.1 log10
(P  0.0001) for lower and higher doses, respectively (Fig. 1J). At
day 7, viral titers in lungs remained high (6.8 log10) in control
IgG-treated mice, while no virus was detected in animals treated
with either dose of 81.39a (Fig. 1J), indicating a strong antiviral
effect despite the delayed treatment.
Infection with either of the A(H7N9) viruses caused 90%
mortality in control IgG-treated animals (Fig. 1L and O). The
lower and higher 81.39a doses protected 14 of 18 (80%; P 
0.0007) and 16 of 18 (90%; P  0.0001) mice inoculated with
the wild-type virus (Fig. 1L). In mice inoculated with the HA2-
Asp19Gly virus, the higher dose of antibody resulted in protection
of 16 of 18 (90%, P  0.0001) mice and the lower dose protected
11 of 18 (60%; P  0.013) (Fig. 1O). Therefore, the diminishing
effect of the HA2-Asp19Gly substitution on survival was only ob-
served at the lower dose of treatment.
The inhibitory effect of 81.39a on virus replication was also
observed in lungs of mice inoculated with the HA2-Asp19Gly
A(H7N9) virus. The lower and higher doses reduced mean lung
viral titers by 1.2 log10 (P  0.002) and 1.5 log10 (P  0.003) at day
5, respectively (Fig. 1M). At 7 dpi, control IgG-treated mice had
high viral titers (6.2 log10), while those that received 81.39a had
significantly lower lung viral titers, 3.7 log10 with 15 mg/kg (P 
0.004) and 3.4 log10 with 45 mg/kg (P  0.001). Overall, the anti-
viral effect of 81.39a was less pronounced in the HA2-Asp19Gly-
infected group than in the mice inoculated with the wild-type
A(H7N9) virus.
Other clinical indices mirrored the antiviral effect observed in
the lungs of 81.39a-treated mice. Disease manifestations such as
lethargy, ruffled fur, hunched posture, and dyspnea were apparent
in control groups infected by either H7N9 virus but were rarely to
occasionally present in the majority of 81.39a-treated animals.
The body weight loss in 81.39a-treated animals was less pro-
nounced and their recovery occurred much faster than that of the
control groups (Fig. 1K and N). The dose-dependent effect of
treatment was not apparent, particularly in mice infected with the
HA2-Asp19Gly virus.
Overall, these data indicate that 81.39a was also effective in
mice infected with a group 2 HA influenza virus, demonstrating
that in vitro antiviral activity is not always a predictive factor of
efficacy in mammalian animal models.
81.39a efficacy against A(H1N1)pdm09 influenza virus in
ferrets. We next utilized a ferret model to assess the effect of
81.39a treatment on viral replication in the upper and lower re-
spiratory tracts. A/California/12/2012, a representative of an
A(H1N1)pdm09 virus, was used to analyze 81.39a effectiveness in
ferrets. A single intravenous treatment was given to ferrets at 24,
48, or 72 hpi to assess the effect of delayed treatment. Either 81.39a
or control IgG was delivered at a dose of 25 mg/kg. Nasal wash
samples were collected from 1 through 5 dpi before animals were
humanely sacrificed to harvest respiratory organs.
Infection of ferrets with the A(H1N1)pdm09 virus caused
moderate to severe signs of disease (Table 3). All inoculated ani-
mals showed 5 to 7% body weight loss and had nasal discharge,
indicative of productive infection. The number of 81.39a-treated
animals that developed fever and demonstrated clinical symp-
toms, namely, sneezing, cough, and labored breathing, was sub-
stantially lower than that of control IgG-treated groups. However,
regardless of treatment, none of these animals had blood oxygen
levels (i.e., saturation of peripheral oxygen [SpO2]) below 90%,
which, if present, would indicate hypoxemia and/or respiratory
failure.
All inoculated animals shed virus throughout the 5-day exper-
iment (Fig. 2A); nasal wash viral titers peaked at day 1 (7 log10),
which is not an unusual phenomenon when a high dose (106
TCID50) of virus is used for inoculation. The 24-h delayed treat-
ment with 81.39a resulted in a significant viral titer reduction (1.3
log10; P  0.016) detected at 3 dpi. When given at 48 hpi, 81.39a
treatment significantly reduced nasal wash viral titer at 3 (1.4
log10; P  0.0007) and 4 (0.7 log10; P  0.046) dpi. Notably, a
statistically significant difference in viral titer reduction was also
detected at 4 dpi, even when 81.39a treatment was delayed for 72 h
(0.7 log10; P  0.009).
The A(H1N1)pdm09 influenza virus replicated in the lung tis-
sues, consistent with previous reports (37, 41, 42). This virus rep-
licated to relatively high titer (4 log10) not only in the nasal
turbinate but also in the trachea and, to some extent, in bron-
choalveolar lavage fluid (BALF) of control IgG-treated ferrets
(Fig. 2B to D) at 5 dpi. When administered at 72 hpi, 81.39a pro-
TABLE 3 Clinical signs in A(H1N1)pdm09-infected ferrets treated with
or without 81.39aa
Parameter
Value by time of treatment (hpi) for:
Control IgG
(24 hpi)
81.39a
24 48 72
No. positive/total no.
Weight loss (% of
maximum)
4/4 (6) 4/4 (6) 4/4 (5) 4/4 (7)
Pyrexiab 3/4 2/4 1/4 2/4
Sneeze (frequency) 4/4 (high) 4/4 (low) 4/4 (moderate) 4/4 (moderate)
Nasal discharge 4/4 4/4 4/4 3/4
Cough 2/4 0/4 0/4 0/4
Dyspnea 2/4 0/4 0/4 0/4
SpO2
c (%) 95–100 95–100 96–100 95–100
a Ferrets (n  4 per group) were infected with 106 TCID50 of A(H1N1)pdm09 virus
and treated with 25 mg/kg of control IgG (gD5237) or 81.39a at 24, 48, or 72 hpi.
b Increase in temperature of 1.5°C compared to the baseline.
c Saturation of peripheral oxygen (SpO2), measured during days 2 to 5 postinoculation.
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duced a noticeable reduction in viral titers (1.2 log10; P  0.0013)
in the nasal turbinate (Fig. 2A); these changes were not statistically
significant for 24- or 48-h-delayed treatment. A more pronounced
effect from 81.39a treatment was found in the trachea and BALF
samples (Fig. 2B and C). Virus was not detected in any of these
samples collected from animals treated with 81.39a at 24 or 72 hpi,
and only one of four ferrets treated with 81.39a at 48 hpi had
detectable viral titers in the trachea (P  0.01 for both time points)
and BALF (P  0.005 for both time points). The results suggest a
superior antiviral activity of 81.39a in the lower respiratory tract
compared to the upper respiratory tract.
Subsequently, we measured the total inflammatory cell num-
ber and protein content in the BALF of ferret at 5 dpi. BALF total
cell numbers were decreased significantly after 81.39a treatment
given at 24 (P  0.004), 48 (P  0.006), or 72 (P  0.008) hpi (Fig.
2D). Although not statistically significant, a trend toward lower
BALF total protein content was found across all 81.39a-treated
groups (Fig. 2E), suggesting that the 81.39a treatment was benefi-
cial in protecting pulmonary tissues from the severe damage that
occurred during viral infections of control IgG-treated ferrets.
81.39a administration alleviates pathological changes in the
lungs of ferret. To further investigate the therapeutic effect of
81.39a in the lower respiratory tract of ferrets, we examined the
pulmonary histopathology and the presence of viral NP in the
lung sections of each lobe of virus-inoculated animals. Lung tis-
sues of control IgG-treated ferrets showed severe multifocal alve-
olar, bronchial, perivascular, and interstitial infiltrates of inflam-
matory cells composed of neutrophils, macrophages, and a few
lymphocytes intermixed with occasional glandular and lymphoid
necrosis, fibrin deposition, and edema (Fig. 3A and Table 4). Con-
gested alveolar walls were found frequently and contained type II
pneumocyte hyperplasia or infiltrates of lymphocytes and macro-
phages. The bronchial and bronchiolar epithelium was necrotic
and mildly hyperplastic. Overall, the pathology damage in lung
samples of control animals was assessed as severe (Table 4). In
contrast, lung samples from 81.39a-treated animals (24- and 48-
h-delayed treatment) displayed moderate degrees of tissue dam-
age (Fig. 3B and C and Table 4). 81.39a also prevented severe
lesions in the lungs when given 72 hpi (Fig. 3D), but its therapeutic
effect was less significant than that of the 24- and 48-h-delayed
FIG 2 Effectiveness of 81.39a treatment in ferrets. Viral titers in nasal washes (NW) (A), nasal turbinates (NT) (B), trachea (TR) (C), and bronchoalveolar lavage
fluid (BALF) (D), as well as inflammatory cell counts (E) and protein concentrations (F) in BALF. Groups of four ferrets were inoculated with 106 TCID50 of
H1N1pdm virus and treated with 25 mg/kg of control IgG or 81.39a at the indicated hours postinoculation. Nasal washes were collected 1 to 5 dpi, while
respiratory tract tissues and BALF were harvested at 5 dpi. All data are expressed as the means 	 SD. In panels B to D, each data point represents the viral titer
of an individual animal. Dotted lines in lung viral titers indicate the limit of detection (1.6 log10). *, P  0.05.
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treatment. This finding showed that a faster tissue recovery took
place in the lungs of 81.39a-treated animals than in those of con-
trol IgG-treated animals.
To confirm that the observed lung damage was caused by virus
replication and to examine the effect of 81.39a administration on
the degree of virus replication in the lungs, we stained lung tissue
samples for viral NP using immunohistochemistry. The lung sec-
tions derived from control animals showed frequent NP stain-
ing in the bronchiolar and peribronchial lymphoid and glan-
dular tissues (Fig. 3D and Table 4). Conversely, the number of
positively NP-stained cells was markedly lower in 81.39a-
treated animals in all regimens tested. Detection of viral NP in
the lungs was rare or only occasional in animals receiving 24-,
48-, or 72-h-delayed treatment (Fig. 3E to G and Table 4).
These data suggest that 81.39a treatment contributed to rapid
elimination of viruses from the lower respiratory tract of virus-
inoculated animals.
FIG 3 Pulmonary histopathology lesions and antigen expression in infected ferrets. Animals were inoculated with 106 TCID50 of A(H1N1)pdm09 virus and
treated with 25 mg/kg of control IgG or 25 mg/kg of 81.39a at 24, 48, or 72 hpi. Lungs were collected from each animal at day 5. Each image was derived from one
sample as a representative of the respective treatment group with four ferrets per group. Viral NP stains are shown by black arrows. Images were taken with 200
magnification. H/E, hematoxylin and eosin stain; IHC, immunohistochemistry.
TABLE 4 Histologic findings in the respiratory tracts of infected ferrets
treated with 81.39a or left untreated
Antiviral and time
of treatment (hpi)
Lung tissue analysisa
Histopathological lesions
(score 	 SD)
Detection of viral
NP
Control IgG
24 Severe (8.5 	 0.5) Frequent
81.39a
24 Moderate (6.3 	 1.1) Rare to occasional
48 Moderate (6.3 	 1.5) Rare to occasional
72 Moderate to severe
(7.0 	 1.6)
Rare to occasional
a Ferrets were inoculated with 106 TCID50 of A(H1N1)pdm09 virus and treated with 25
mg/kg of control IgG (gD5237) at 24 hpi or 81.39a at 24, 48, or 72 hpi. Each data point
	 SD represents the mean score of histopathological lesions from 4 animals per group.
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DISCUSSION
Here, we demonstrate the broad neutralization activity of human
MAb 81.39a, which targets influenza A viruses of HA groups 1 and
2, using a comprehensive panel of influenza A viruses encompass-
ing 16 HA subtypes (23 viruses from group 1 and 17 from group
2). This panel contained viruses collected from various geographic
locations and included seasonal viruses, zoonotic viruses, HPAI
A(H5N2) and A(H5N8) viruses, subtypes responsible for an un-
precedented outbreak in poultry in the U.S., and virus variants
resistant to one or both classes of FDA-approved anti-influenza
drugs. The strength of this study is the direct testing of this diverse
group of viruses using the same in vitro neutralization method,
while previous studies on group 1- and 2-targeting MAbs only
tested selected subtypes in the neutralization assay (21–25). In
addition, conclusions of the reported subtype coverage were made
based on the antibody binding to recombinant proteins or results
from neutralization assays using pseudotyped viruses. It is note-
worthy that the ability of bnAbs to bind to different HA subtypes
does not always prove that they also neutralize virus infectivity, as
shown with FJ76 (22). This phenomenon might not be uncom-
mon for HA stalk-targeting antibodies. Factors which could influ-
ence the neutralization ability of an antibody include the strength
of binding affinity and the location of binding sites within the HA
stalk.
The EC50s ranged widely (500-fold), from 0.01 to 4.85 g/
ml, and there was no consistent difference between group 1 and
group 2 viruses. The EC50s determined in our study were similar
to those reported for viruses tested with the parental MAb 81.39
(0.65 to 26.3 nM, corresponding to 0.10 to 4.11 g/ml) (21). Sev-
eral mechanisms of in vitro neutralization by MAbs were previ-
ously demonstrated, such as prevention of cleavage by cellular
protease needed for HA maturation, interference with the fusion
between viral and endosomal membranes via binding to a mono-
meric HA or cross-linking the neighboring HA molecules, and
potential disruption of viral egress (22, 25, 43). Accessibility to the
antibody epitope seems to be favored when HA molecules are
expressed on the surface of infected cells rather than on the surface
of the virion (22). Indeed, in our study, virus preincubation with
81.39a had a negligible effect on EC50s. In contrast, the impact of
the MAb’s presence during viral replication steps in cells, where it
can bind to newly synthesized HA molecules, was evident (Table
5). Taken together, these results are consistent with the proposed
dual effect of bnAbs on virus infection: binding to HA prevents the
early stage of viral replication, most likely by interference with
fusion, and later, binding to HA expressed on the surface of in-
fected cells disrupts the formation of infectious particles and their
spread to neighboring cells (22).
In this study, viruses whose neutralization by 81.39a was abro-
gated in the neutralization assay had Asp at position HA2-19 re-
placed with Asn, Ala, or Gly. All but one virus belong to H11, H12,
H13, and H16 subtypes (group 1), which are not known to cause
human infections. A single virus from group 2, a drug-resistant
A(H7N9) clone, had HA2-Asp19Gly. It is noteworthy that substi-
tutions at this position are rarely found among A(H7N9) virus
recovered from humans. The HA2-Asp19Gly virus escaped neu-
tralization by 81.39a at a concentration of 50 g/ml. However,
when the MAb concentration was increased to 300 g/ml, some
degree of inhibition of virus infectivity was observed, suggesting a
therapeutic benefit of higher drug doses. It is worth noting that
while group 1-targeting MAbs D8 and F10 effectively neutralized
a pseudotyped virus of H11 subtype carrying Asp19Asn (40), a
lack of neutralization of H3 and H7 subtype viruses carrying this
change was reported for CR8020, a group 2-neutralizing MAb
(44). The lack of neutralizing activity toward viruses with Asp19
substitutions may be explained by previous structural studies. For
instance, residue Asp19 was shown to lie within the epitope, rec-
ognized by the light chain of 39.29, which competes with 81.39 for
overlapping regions (21). Therefore, a substitution at Asp19 may
also affect the binding affinity of 81.39a under our in vitro neutral-
ization assay conditions. Further, Asp19Asn was demonstrated to
abrogate neutralization of A(H3N2) and A(H7N7) viruses by
CR8020 (44), where HA2-Asp19Asn is believed to disrupt a pos-
sible salt bridge to VL of arginine at position 53, leading to desta-
bilization of the antibody-HA interaction.
Peculiarly, for the group 1- and 2-targeting MAb CR9114, the
effect of substitution HA2-Asp19Asn on binding affinity varied
among HA subtypes. Asp19Asn reduced the binding affinity (Kd
[dissociation constant]  570 nM) in the H3 subtype, while the
binding affinity of the H13 (Kd  6.3 nM) and H16 (Kd  20 nM)
subtypes carrying HA2-Asn19 was similar to that of the H3 sub-
type carrying HA2-Asp19 (Kd  33 nM) (23). Moreover, binding
to H9 and H12 subtypes carrying HA2-Asp19Ala was not affected
(Kd of 2 and 2.9, respectively), similar to that of the H1 subtype.
The H9 and H12 subtypes are phylogenetically closely related;
H12 belongs to the H9 cluster of group 1 HA (39, 40). In our study,
however, the effect of HA2-Asp19Ala on virus neutralization by
81.39a was different, indicating the distinctive features of each
stalk-binding MAb, and underscores the importance of actual
TABLE 5 Neutralization activity of 81.39a added at different steps of viral replication
No. Virus HA subtype NA substitution
EC50, g/ml (n-fold), for step
a:
Ab Bc Cd
1 A/California/12/2012 A(H1N1)pdm09 1.29 	 0.23 3.24 	 1.09 (3) NT
2 A/Texas/23/2012 A(H1N1)pdm09 H274Y 0.75 	 0.24 5.22 	 3.84 (7) NT
3 A/Maryland/08/2013 A(H1N1)pdm09 0.58 	 0.04 10.09 	 8.72 (17) 0.54 	 0.22 (1)
4 A/Louisiana/08/2013 A(H1N1)pdm09 H274Y 0.59 	 0.43 10.02 	 2.62 (17) 0.65 	 0.26 (1)
5 A/Wuhan/359/1995-like A(H3N2) 1.23 	 0.18 12.92 	 3.67 (11) NT
6 A/Wuhan/359/1995-like A(H3N2) E119V 1.06 	 0.11 9.94 	 1.66 (9) NT
a EC50s were derived from at least three replicates for each virus per experiment. n-fold indicates the fold increase in EC50 compared to step A. NT, not tested.
b Virus was preincubated for 1 h with 81.39a, followed by 1 h of virus adsorption. The MAb was present in cell overlay throughout the experiment.
c Virus was preincubated for 1 h with 81.39a, followed by 1 h of virus adsorption. Thereafter, inoculum was removed and cells were washed 2 with PBS; no MAb was in the cell
overlay.
d Virus was preincubated for 1 h without 81.39a, followed by 1 h of virus adsorption. The MAb was present in cell overlay throughout the experiment.
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testing of viruses in neutralization assays. Because avian A(H9N2)
viruses are known to infect humans (45, 46), there is added utility
in demonstrating the ability of 81.39a to neutralize these viruses.
In the mouse model, we used four zoonotic viruses, HPAI
A(H5N2), A(H5N8), A(H6N1), and A(H7N9), which showed
similar EC50s in the neutralization assay. Both H5Nx viruses used
in this study have been shown to efficiently replicate in the lungs of
mice without prior adaptation (36). Regardless of virus used, a
single dose of 1-day-delayed treatment with 81.39a protected an-
imals from weight loss, rescued 90% of animals from the lethal
challenge, and resulted in an undetectable level of virus titers in
the inoculated animals at 6 dpi. Further, even the single, 2-day-
delayed treatment showed significant reduction in viral titers in
lungs of mice inoculated with either A(H6N1) or A(H7N9) virus.
Each virus was cleared by 7 dpi, and mice survived the lethal chal-
lenge, while 90 to 100% of control IgG-treated animals suc-
cumbed to infection. The in vivo effectiveness of delayed treat-
ment using group 1- and 2-targeting bnAbs, such as 39.29, 81.39,
FI6, FI6v3, CT149, 045-051310-2B06, S6-B01, 07-5E01, 41-5D06,
and 41-5E04, was also demonstrated in animal models (21, 22, 25,
28, 30).
Interestingly, we observed the therapeutic benefit from 81.39a
treatment in mice infected with the A(H7N9) virus carrying HA2-
Asp19Gly despite its lack of neutralization in cell culture. Simi-
larly, the MAbs VIS410 (27) and 1H5 (47), as well as 41-5D06,
07-5E01, and 24-4C01 (30), were also shown to protect mice from
lethal infections with H7N9 virus, although it failed to neutralize
the virus in vitro. Another prime example is CR9114, which binds
to influenza B HA and is protective against influenza B challenge;
however, this MAb only neutralizes influenza A and not influenza
B viruses (23). Therefore, in vitro neutralization may not be com-
pletely predictive of in vivo potency. The results also suggest the
involvement of cellular factors in vivo that are lacking in the cell
culture system. A previous report indicated that interactions be-
tween the fragment crystallizable (Fc) region of broadly neutral-
izing HA stalk-specific antibodies and Fc receptors (Fc
Rs) for
IgG are required for protection against influenza virus in vivo (48).
In agreement, an Fc mutant of FI6, lacking both complement and
Fc
R binding, exhibits 60% less protective efficacy in mice (22),
strengthening the importance of Fc
R binding in mediating in vivo
efficacy. One or more of these mechanisms could contribute to the
therapeutic benefits observed for 81.39a against HA2-Asp19Gly-car-
rying A(H7N9) viruses in vivo: antibody-dependent cell-mediated
cytotoxicity (ADCC), antibody-dependent cellular phagocytosis
(ADCP), antibody-dependent respiratory burst (ADRB) activity,
and complement-dependent cytotoxicity (CDC). A similar in vivo
phenomenon was also observed with MAbs 1H5 and 1H10, de-
spite the lack of remarkable in vitro neutralizing activity (47).
In the ferret model, the antiviral effect of delayed 81.39a treat-
ment was analyzed both in the upper and lower respiratory tracts.
While viral titers in nasal washes and nasal turbinate were moder-
ately reduced, a stronger inhibition of viral replication was de-
tected in the trachea and BALF after a single-dose administration
of 81.39a, indicative of a higher level of 81.39a activity in the lower
respiratory tract compared to the upper respiratory tract. This
result was further supported by lung tissue analyses showing a
strong reduction of viral NP expression upon 81.39a treatment. In
addition, histopathological analyses demonstrate that lung tissues
of an uninfected ferret treated with 81.39a displayed no significant
lesion, similar to what is observed in lung tissues of an uninfected
and untreated control animal (data not shown), indicating that
treatment with 81.39a exerts no apparent toxicity.
A previous study suggested that IgA is more efficiently trans-
ported to mucosal surfaces, while IgG is found predominantly in
the lungs of influenza virus-infected animals (49, 50). Therefore, a
lesser antiviral effect of IgG in the upper respiratory tract is ex-
pected, which may account for a modest reduction in nasal wash
viral titers of 81.39a (IgG)-treated ferrets. Consistent with our
finding, another study has shown that serum and lung antibody
titers of H1 stalk-specific 6F12 (IgG)-treated ferrets were present
in relatively high concentrations at 4 dpi, while the nasal wash
antibody titer was similar to that of the negative control on day 3
(51). A pool of the IgA and IgG stalk-targeting antibody mixture
may therefore improve the overall therapeutic effect by providing
a better location-specific antibody distribution both in the upper
and lower respiratory tracts.
To the best of our knowledge, this is the first study in which all
16 HA subtypes of influenza A viruses present in aquatic birds and
mammals were used to evaluate a group 1- and 2-targeting bnAb
in the neutralization assay. Our data demonstrate that treatment
administration of 81.39a is effective in protecting mammals from
disease caused by emerging influenza viruses, including H5Nx
viruses. Collectively, this study revealed experimental evidence of
the therapeutic potential of 81.39a and provided a basis for future
clinical trials.
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